Clinical Trial Update: A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) [Phase 3]

View source ↗

Summary

Phase 3 trial of the VLP-based chikungunya vaccine PXVX0317 has completed and results have been posted. Sponsor Bavarian Nordic conducted the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya

Drugs mentioned

• PXVX0317 (CHIKV VLP Vaccine)

Snippet

Sponsor: Bavarian Nordic | Conditions: Chikungunya Virus | Phase 3 | Status: COMPLETED | Results posted: 2024-08-30